Equivocal ALK fluorescence in-situ hybridization (FISH) cases may benefit from ancillary ALK FISH probe testing
Christina Selinger, Wendy Cooper, Trina Lum, Catriona McNeil, Adrienne Morey, Paul Waring, Benhur Amanuel, Michael Millward, Joanne Peverall, Chris Van Vliet, Michael Christie, Yen Tran, Connie Diakos, Nick Pavlakis, Anthony J Gill, Sandra O'Toole
HISTOPATHOLOGY | WILEY-BLACKWELL | Published : 2015
AIMS: Accurate assessment of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small-cell lung cancers (NSCLCs) is critical to identify patients who are likely to respond to crizotinib. The aim of this study was to evaluate the ALK/EML4 TriCheck FISH probe in a series of NSCLCs enriched for tumours with equivocal ALK status. METHODS AND RESULTS: ALK FISH was prospectively performed on 45 NSCLCs with the ALK/EML4 TriCheck probe (ZytoVision) and the Vysis ALK break-apart probe (Abbott Molecular). ALK immunohistochemistry was performed with 5A4 and D5F3 antibodies. Fourteen cases had equivocal ALK status, based on borderline or focal FISH positivity, an atypical FISH pattern, or discre..View full abstract
We thank the National Foundation for Medical Research and Innovation and the Sydney Breast Cancer Foundation for their generous support and funding for this study.